Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 302, Issue 6, 2012, Pages

  Maloney, James P ^a,b   Stearman, Robert S ^a   Bull, Todd M ^a   Calabrese, David W ^a   Tripp Addison, Megan L ^a   Wick, Marilee J ^a   Broeckel, Ulrich ^c   Robbins, Ivan M ^d   Wheeler, Lisa A ^d   Cogan, Joy D ^d   Loyd, James E ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b Veterans Affairs Eastern Colorado Healthcare System   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelium; Genetics; Matricellular proteins; Vascular smooth muscle

Indexed keywords

MUTANT PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAZ; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HEREDITARY HYPERTENSION; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BINDING SITES; CELL GROWTH PROCESSES; CELLS, CULTURED; COHORT STUDIES; CONSERVED SEQUENCE; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTRONS; MALE; MUTATION, MISSENSE; MYOCYTES, SMOOTH MUSCLE; POLYMORPHISM, GENETIC; PROTEIN BINDING; PULMONARY ARTERY; RNA SPLICING; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84858176165     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00282.2011     Document Type: Article

References (72)

1. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216: 276-284, 1994.
2. Almeida-Vega S, Catlow K, Kenny S, Dimaline R, Varro A. Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1. Am J Physiol Gastrointest Liver Physiol 296: G414-G423, 2009.
3. Ashfield R, Patel AJ, Bossone SA, Brown H, Campbell RD, Marcu KB, Proudfoot NJ. MAZ-dependent termination between closely spaced human complement genes. EMBO J 13: 5656-5667, 1994.
4. Bossone SA, Asselin C, Patel AJ, Marcu KB. MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. Proc Natl Acad Sci USA 89: 7452-7456, 1992.
5. Botella LM, Sanchez-Elsner T, Rius C, Corbi A, Bernabeu C. Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 276: 34486-34494, 2001.
6. Botney MD, Kaiser LR, Cooper JD, Mecham RP, Parghi D, Roby J, Parks WC. Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol 140: 357-364, 1992.
7. Boukerche H, Berthier-Vergnes O, Tabone E, Bailly M, Dore JF, McGregor JL. Thrombospondin modulates melanoma-platelet interactions and melanoma tumour cell growth in vivo. Br J Cancer 72: 108-116, 1995.
8. Cogan JD, Pauciulo MW, Batchman AP, Prince MA, Robbins IM, Hedges LK, Stanton KC, Wheeler LA, Phillips JA 3rd, Loyd JE, Nichols WC. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 590-598, 2006.
9. Courey AJ, Holtzman DA, Jackson SP, Tjian R. Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 59: 827-836, 1989.
10. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93: 1159-1170, 1998.
11. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138: 707-717, 1997.
12. Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 23: 193-200, 2005.
13. Fike CD, Slaughter JC, Kaplowitz MR, Zhang Y, Aschner JL. Reactive oxygen species from NADPH oxidase contribute to altered pulmonary vascular responses in piglets with chronic hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 295: L881-L888, 2008.
14. Freishtat RJ, Benton AS, Watson AM, Wang Z, Rose MC, Hoffman EP. Delineation of a gene network underlying the pulmonary response to oxidative stress in asthma. J Investig Med 57: 756-764, 2009.
15. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Patel S, Nelson SF, Horvath S, Berliner JA, Kirchgessner TG, Lusis AJ. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci USA 103: 12741-12746, 2006.
16. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624-6628, 1990.
17. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57: 1735-1742, 1997.
18. He B, Weber GF. Synergistic activation of the CMV promoter by NF-kappaB P50 and PKG. Biochem Biophys Res Commun 321: 13-20, 2004.
19. Hong KH, Lee YJ, Lee E, Park SO, Han C, Beppu H, Li E, Raizada MK, Bloch KD, Oh SP. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 118: 722-730, 2008.
20. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423-1431, 1999.
21. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 284: 1116-1125, 2009.
22. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109: 1945-1952, 2007.
23. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for antiangiogenic therapies. Nat Rev Cancer 9: 182-194, 2009.
24. Ishimura-Oka K, Semenkovich CF, Faustinella F, Goldberg IJ, Shachter N, Smith LC, Coleman T, Hide WA, Brown WV, Oka K, Chan L. A missense (Asp250¡Asn) mutation in the lipoprotein lipase gene in two unrelated families with familial lipoprotein lipase deficiency. J Lipid Res 33: 745-754, 1992.
25. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, Dartevelle P, Simonneau G, Adnot S, Maitre B, Raffestin B, Eddahibi S. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119: 512-523, 2009.
26. Izzo MW, Strachan GD, Stubbs MC, Hall DJ. Transcriptional repression from the c-myc P2 promoter by the zinc finger protein ZF87/MAZ. J Biol Chem 274: 19498-19506, 1999.
27. Jaffe E, Bornstein P, Disteche CM. Mapping of the thrombospondin gene to human chromosome 15 and mouse chromosome 2 by in situ hybridization. Genomics 7: 123-126, 1990.
28. Ji C, Casinghino S, McCarthy TL, Centrella M. Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor. J Biol Chem 272: 21260-21267, 1997.
29. Jones LJ, Gray M, Yue ST, Haugland RP, Singer VL. Sensitive determination of cell number using the CyQUANT cell proliferation assay. J Immunol Methods 254: 85-98, 2001.
30. Karagiannis ED, Popel AS. A systematic methodology for proteomewide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci USA 105: 13775-13780, 2008.
31. Karantzoulis-Fegaras F, Antoniou H, Lai SL, Kulkarni G, D'Abreo C, Wong GK, Miller TL, Chan Y, Atkins J, Wang Y, Marsden PA. Characterization of the human endothelial nitric-oxide synthase promoter. J Biol Chem 274: 3076-3093, 1999.
32. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 285: 38923-38932, 2010.
33. Koch AE, Friedman J, Burrows JC, Haines GK, Bouck NP. Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology 61: 1-6, 1993.
34. Koehler R, Grunig E, Pauciulo MW, Hoeper MM, Olschewski H, Wilkens H, Halank M, Winkler J, Ewert R, Bremer H, Kreuscher S, Janssen B, Nichols WC. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. J Med Genet 41: e127, 2004.
35. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 147: 1759-1769, 1995.
36. Laherty CD, Gierman TM, Dixit VM. Characterization of the promoter region of the human thrombospondin gene. DNA sequences within the first intron increase transcription. J Biol Chem 264: 11222-11227, 1989.
37. Lawler J, Hynes RO. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 103: 1635-1648, 1986.
38. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101: 982-992, 1998.
39. Lefkowitz JB, Nuss R, Haver T, Jacobson L, Thompson AR, Manco-Johnson M. Factor IX Denver, ASN 346-ASP mutation resulting in a dysfunctional protein with defective factor VIIIa interaction. Thromb Haemost 86: 862-870, 2001.
40. Lin CS, Chow S, Lau A, Tu R, Lue TF. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 14: 15-24, 2002.
41. Liu Y, Mosher DF. Interactions among stalk modules of thrombospondin-1. J Biol Chem 284: 28563-28570, 2009.
42. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, Glissmeyer E, Carlquist J, Kim M, Torbicki A, Fijalkowska A, Szewczyk G, Parma J, Abramowicz MJ, Galie N, Morisaki H, Kyotani S, Nakanishi N, Morisaki T, Humbert M, Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell NW, Trembath RC. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 27: 121-132, 2006.
43. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68: 92-102, 2001.
44. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, Aspden RM, Ralston SH. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 107: 899-907, 2001.
45. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 102: 4399-4406, 2003.
46. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC. Hyperproliferative apoptosisresistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548-L554, 2007.
47. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482, 2002.
48. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, Lawler J. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61: 7830-7839, 2001.
49. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104: 790-795, 2001.
50. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 29: 2379-2381, 2002.
51. Newman JH, Phillips JA, 3rd, Loyd JE. Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med 148: 278-283, 2008.
52. Ochoa CD, Baker H, Hasak S, Matyal R, Salam A, Hales CA, Hancock W, Quinn DA. Cyclic stretch affects pulmonary endothelial cell control of pulmonary smooth muscle cell growth. Am J Respir Cell Mol Biol 39: 105-112, 2008.
53. Ochoa CD, Hasak SL, Al-Ansari E, Yu L, Hales CA, Quinn DA. Thrombospondin-1 in hypoxic pulmonary vascular remodeling. FASEB J 21: A1434-A1435, 2007.
54. Ochoa CD, Yu L, Al-Ansari E, Hales CA, Quinn DA. Thrombospondin- 1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg 5: 32, 2010.
55. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19: 563-571, 2008.
56. Parks CL, Shenk T. The serotonin 1a receptor gene contains a TATAless promoter that responds to MAZ and Sp1. J Biol Chem 271: 4417-4430, 1996.
57. Qabar AN, Bullock J, Matej L, Polverini P. Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins. Biochem J 346: 147-153, 2000.
58. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 118: 2372-2379, 2008.
59. Sage E, Mercier O, Van den Eyden F, de Perrot M, Barlier-Mur AM, Dartevelle P, Eddahibi S, Herve P, Fadel E. Endothelial cell apoptosis in chronically obstructed and reperfused pulmonary artery. Respir Res 9: 19, 2008.
60. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, Murphy-Ullrich JE. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270: 7304-7310, 1995.
61. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 269: 26775-26782, 1994.
62. Shamis Y, Hasson E, Soroker A, Bassat E, Shimoni Y, Ziv T, Sionov RV, Mitrani E. Organ-specific scaffolds for in vitro expansion, differentiation, and organization of primary lung cells. Tissue Eng Part C Methods 17: 861-870.
63. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168: 643-653, 2005.
64. Song J, Ugai H, Ogawa K, Wang Y, Sarai A, Obata Y, Kanazawa I, Sun K, Itakura K, Yokoyama KK. Two consecutive zinc fingers in Sp1 and in MAZ are essential for interactions with cis-elements. J Biol Chem 276: 30429-30434, 2001.
65. Subramanian SV, Polikandriotis JA, Kelm RJ Jr, David JJ, Orosz CG, Strauch AR. Induction of vascular smooth muscle alpha-actin gene transcription in transforming growth factor beta1-activated myofibroblasts mediated by dynamic interplay between the Pur repressor proteins and Sp1/Smad coactivators. Mol Biol Cell 15: 4532-4543, 2004.
66. Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 8: 471-479, 1997.
67. Wang IM, Stepaniants S, Boie Y, Mortimer JR, Kennedy B, Elliott M, Hayashi S, Loy L, Coulter S, Cervino S, Harris J, Thornton M, Raubertas R, Roberts C, Hogg JC, Crackower M, O'Neill G, Pare PD. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 177: 402-411, 2008.
68. Wight TN, Raugi GJ, Mumby SM, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 33: 295-302, 1985.
69. Yanai H, Chiba H, Morimoto M, Abe K, Fujiwara H, Fuda H, Hui SP, Takahashi Y, Akita H, Jamieson GA, Kobayashi K, Matsuno K. Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. Am J Med Genet 93: 299-304, 2000.
70. Yao M, Roberts DD, Isenberg JS. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res 63: 13-22, 2011.
71. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, Easley RB, McVerry BJ, Tuder RM, Standiford T, Brower RG, Barnes KC, Garcia JG. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171: 361-370, 2005.
72. Young GD, Murphy-Ullrich JE. The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 279: 47633-47642, 2004.